Overview
High-grade neuroendocrine carcinoma of the cervix uteri is an extremely rare and aggressive malignant tumor arising from neuroendocrine cells in the uterine cervix. This cancer encompasses two main histological subtypes: small cell neuroendocrine carcinoma (SCNEC) and large cell neuroendocrine carcinoma (LCNEC) of the cervix. It accounts for a very small percentage of all cervical cancers. The disease primarily affects the reproductive system but is notable for its propensity for early lymphovascular invasion and distant metastasis, commonly spreading to the lungs, liver, bone, and brain. Human papillomavirus (HPV) infection, particularly HPV types 16 and 18, has been strongly associated with the development of this tumor. Key symptoms include abnormal vaginal bleeding (postcoital, intermenstrual, or postmenopausal), vaginal discharge, and pelvic pain. In advanced stages, patients may experience symptoms related to metastatic spread, such as weight loss, fatigue, and organ-specific symptoms depending on the sites of metastasis. Some patients may also develop paraneoplastic syndromes due to ectopic hormone production by the neuroendocrine tumor cells, though this is uncommon. Due to its rarity, there are no standardized treatment protocols, but management typically involves a multimodal approach combining radical surgery, platinum-based chemotherapy (often cisplatin and etoposide, analogous to regimens used for small cell lung cancer), and radiation therapy. Despite aggressive treatment, the prognosis remains poor compared to more common cervical cancer types such as squamous cell carcinoma, with high rates of recurrence and distant metastasis. Early-stage disease may have a somewhat better outcome, but advanced-stage disease carries a significantly reduced survival rate. Clinical trials and emerging immunotherapy approaches are being explored to improve outcomes for affected patients.
Also known as:
Sporadic
Usually appears on its own, not inherited from a parent
Adult
Begins in adulthood (age 18 or older)
Treatments
No FDA-approved treatments are currently listed for High-grade neuroendocrine carcinoma of the cervix uteri.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for High-grade neuroendocrine carcinoma of the cervix uteri at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to High-grade neuroendocrine carcinoma of the cervix uteri.
Community
No community posts yet. Be the first to share your experience with High-grade neuroendocrine carcinoma of the cervix uteri.
Start the conversation →Latest news about High-grade neuroendocrine carcinoma of the cervix uteri
1 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about High-grade neuroendocrine carcinoma of the cervix uteri
What is High-grade neuroendocrine carcinoma of the cervix uteri?
High-grade neuroendocrine carcinoma of the cervix uteri is an extremely rare and aggressive malignant tumor arising from neuroendocrine cells in the uterine cervix. This cancer encompasses two main histological subtypes: small cell neuroendocrine carcinoma (SCNEC) and large cell neuroendocrine carcinoma (LCNEC) of the cervix. It accounts for a very small percentage of all cervical cancers. The disease primarily affects the reproductive system but is notable for its propensity for early lymphovascular invasion and distant metastasis, commonly spreading to the lungs, liver, bone, and brain. Huma
How is High-grade neuroendocrine carcinoma of the cervix uteri inherited?
High-grade neuroendocrine carcinoma of the cervix uteri follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does High-grade neuroendocrine carcinoma of the cervix uteri typically begin?
Typical onset of High-grade neuroendocrine carcinoma of the cervix uteri is adult. Age of onset can vary across affected individuals.
Which specialists treat High-grade neuroendocrine carcinoma of the cervix uteri?
1 specialists and care centers treating High-grade neuroendocrine carcinoma of the cervix uteri are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.